Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and NK Immunotherapy for Metastatic Solid Tumors
NCT02857920Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of HANK cells in solid tumor, sponsored by Fuda Cancer Hospital. Started Aug 2016; status: completed.
02
Drugs
HANK cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02857920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02857920.